Degarelix Acetate (Firmagon®)

Common name: Degarelix Acetate
Brand name: Firmagon®
 

What is Degarelix Acetate?

Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced (metastatic) prostate cancer by blocking the release of testosterone.
 

How is Degarelix Acetate administered?

Degarelix Acetate is administered by subcutaneous injection in the abdominal area.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received degarelix acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Breast enlargement
  • Constipation
  • Difficulties sleeping
  • Fatigue
  • Frequent urination
  • Headaches
  • Hot flashes
  • Nausea
  • Pain / redness at site of injection
  • Reduced sex drive (low libido)


Is Degarelix Acetate covered in my province or territory?

Degarelix acetate is covered by provincial drug programs in:
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland and Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
​Degarelix acetate is not covered by provincial drug program in:
  • ​Alberta

 

Firmagon Care Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Go to http://www.ferring.ca/en/patient-assistance-programs/ for more information and to see if you qualify for this program. Patients can call 1-866-210-0399 for access to a free nurse injection clinic.
 

 

Last Reviewed: July 2017








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive